Antibody Response to SARS-CoV-2 Vaccination in Patients With Lymphoproliferative Disorders and Plasma Cell Dyscrasias: Anti-Lymphoma Therapy as a Predictive Biomarker of Response to Vaccination
We retrospectively analyzed SARS-CoV-2 vaccination antibody responses in a cohort of 273 patients with lymphoproliferative disorders or plasma cell dyscrasias who were seen at a single tertiary cancer center. Semi-quantitative anti-spike protein serologic testing was performed with enzyme immunoassa...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.840451/full |
| _version_ | 1811325886691016704 |
|---|---|
| author | Carol Gung Regina McGuire Mercy George Abdullateef Abdulkareem Katherine A. Belden Pierluigi Porcu Ubaldo Martinez-Outschoorn Adam F. Binder Inna Chervenova Onder Alpdogan |
| author_facet | Carol Gung Regina McGuire Mercy George Abdullateef Abdulkareem Katherine A. Belden Pierluigi Porcu Ubaldo Martinez-Outschoorn Adam F. Binder Inna Chervenova Onder Alpdogan |
| author_sort | Carol Gung |
| collection | DOAJ |
| description | We retrospectively analyzed SARS-CoV-2 vaccination antibody responses in a cohort of 273 patients with lymphoproliferative disorders or plasma cell dyscrasias who were seen at a single tertiary cancer center. Semi-quantitative anti-spike protein serologic testing was performed with enzyme immunoassay method. We found that the antibody response rate to SARS-CoV-2 vaccination was 74.7% in our patient cohort with no difference based on gender, age or race. The highest response rate was found in patients with Multiple Myeloma (MM) (95.5%). The response rates found in Diffuse Large B-Cell Lymphoma (DLBCL), Chronic Lymphocytic Leukemia (CLL), and Low-Grade Non-Hodgkin Lymphoma (LG-NHL) were 73.2%, 61.5% and 53% respectively. We also evaluated the effects of receiving active chemo-immunotherapy on SARS-CoV-2 vaccination antibody response. We found that the patients on treatment had lower response than the patients off treatment (62.1% versus 84.4% p<0.001). Thirty-four of 58 LG-NHL patients were receiving anti-lymphoma treatment with a lower SARS-CoV-2 vaccination response as compared to the patients who were not on treatment (29.4% v 87.5% p<0.001). We observed a similar pattern in CLL patients receiving treatment (48.1 v 76.0 p:0.049). We found that only disease type and treatment status (on-treatment vs. off- treatment), but not gender, age or race were significant predictors of non-response in the multivariable logistic regression model. The interaction between disease type and treatment status was not statistically significant by multivariate analysis. In conclusion, receiving anti-cancer treatment was found to play a significant role in decreasing the response to COVID-19 vaccination. |
| first_indexed | 2024-04-13T14:41:20Z |
| format | Article |
| id | doaj.art-384760bc3234416d81cca66b171bbaba |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-13T14:41:20Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-384760bc3234416d81cca66b171bbaba2022-12-22T02:42:53ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-07-011210.3389/fonc.2022.840451840451Antibody Response to SARS-CoV-2 Vaccination in Patients With Lymphoproliferative Disorders and Plasma Cell Dyscrasias: Anti-Lymphoma Therapy as a Predictive Biomarker of Response to VaccinationCarol Gung0Regina McGuire1Mercy George2Abdullateef Abdulkareem3Katherine A. Belden4Pierluigi Porcu5Ubaldo Martinez-Outschoorn6Adam F. Binder7Inna Chervenova8Onder Alpdogan9Division of Hematologic Malignancies, Department of Medical Oncology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United StatesSidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United StatesDivision of Hematologic Malignancies, Department of Medical Oncology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United StatesDivision of Hematologic Malignancies, Department of Medical Oncology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United StatesDivision of Infectious Diseases, Department of Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United StatesDivision of Hematologic Malignancies, Department of Medical Oncology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United StatesDivision of Hematologic Malignancies, Department of Medical Oncology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United StatesDivision of Hematologic Malignancies, Department of Medical Oncology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United StatesDivision of Biostatistics, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United StatesDivision of Hematologic Malignancies, Department of Medical Oncology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United StatesWe retrospectively analyzed SARS-CoV-2 vaccination antibody responses in a cohort of 273 patients with lymphoproliferative disorders or plasma cell dyscrasias who were seen at a single tertiary cancer center. Semi-quantitative anti-spike protein serologic testing was performed with enzyme immunoassay method. We found that the antibody response rate to SARS-CoV-2 vaccination was 74.7% in our patient cohort with no difference based on gender, age or race. The highest response rate was found in patients with Multiple Myeloma (MM) (95.5%). The response rates found in Diffuse Large B-Cell Lymphoma (DLBCL), Chronic Lymphocytic Leukemia (CLL), and Low-Grade Non-Hodgkin Lymphoma (LG-NHL) were 73.2%, 61.5% and 53% respectively. We also evaluated the effects of receiving active chemo-immunotherapy on SARS-CoV-2 vaccination antibody response. We found that the patients on treatment had lower response than the patients off treatment (62.1% versus 84.4% p<0.001). Thirty-four of 58 LG-NHL patients were receiving anti-lymphoma treatment with a lower SARS-CoV-2 vaccination response as compared to the patients who were not on treatment (29.4% v 87.5% p<0.001). We observed a similar pattern in CLL patients receiving treatment (48.1 v 76.0 p:0.049). We found that only disease type and treatment status (on-treatment vs. off- treatment), but not gender, age or race were significant predictors of non-response in the multivariable logistic regression model. The interaction between disease type and treatment status was not statistically significant by multivariate analysis. In conclusion, receiving anti-cancer treatment was found to play a significant role in decreasing the response to COVID-19 vaccination.https://www.frontiersin.org/articles/10.3389/fonc.2022.840451/fullvaccinationCovid-19immune responsehematologic malignancieschemotherapy. |
| spellingShingle | Carol Gung Regina McGuire Mercy George Abdullateef Abdulkareem Katherine A. Belden Pierluigi Porcu Ubaldo Martinez-Outschoorn Adam F. Binder Inna Chervenova Onder Alpdogan Antibody Response to SARS-CoV-2 Vaccination in Patients With Lymphoproliferative Disorders and Plasma Cell Dyscrasias: Anti-Lymphoma Therapy as a Predictive Biomarker of Response to Vaccination Frontiers in Oncology vaccination Covid-19 immune response hematologic malignancies chemotherapy. |
| title | Antibody Response to SARS-CoV-2 Vaccination in Patients With Lymphoproliferative Disorders and Plasma Cell Dyscrasias: Anti-Lymphoma Therapy as a Predictive Biomarker of Response to Vaccination |
| title_full | Antibody Response to SARS-CoV-2 Vaccination in Patients With Lymphoproliferative Disorders and Plasma Cell Dyscrasias: Anti-Lymphoma Therapy as a Predictive Biomarker of Response to Vaccination |
| title_fullStr | Antibody Response to SARS-CoV-2 Vaccination in Patients With Lymphoproliferative Disorders and Plasma Cell Dyscrasias: Anti-Lymphoma Therapy as a Predictive Biomarker of Response to Vaccination |
| title_full_unstemmed | Antibody Response to SARS-CoV-2 Vaccination in Patients With Lymphoproliferative Disorders and Plasma Cell Dyscrasias: Anti-Lymphoma Therapy as a Predictive Biomarker of Response to Vaccination |
| title_short | Antibody Response to SARS-CoV-2 Vaccination in Patients With Lymphoproliferative Disorders and Plasma Cell Dyscrasias: Anti-Lymphoma Therapy as a Predictive Biomarker of Response to Vaccination |
| title_sort | antibody response to sars cov 2 vaccination in patients with lymphoproliferative disorders and plasma cell dyscrasias anti lymphoma therapy as a predictive biomarker of response to vaccination |
| topic | vaccination Covid-19 immune response hematologic malignancies chemotherapy. |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.840451/full |
| work_keys_str_mv | AT carolgung antibodyresponsetosarscov2vaccinationinpatientswithlymphoproliferativedisordersandplasmacelldyscrasiasantilymphomatherapyasapredictivebiomarkerofresponsetovaccination AT reginamcguire antibodyresponsetosarscov2vaccinationinpatientswithlymphoproliferativedisordersandplasmacelldyscrasiasantilymphomatherapyasapredictivebiomarkerofresponsetovaccination AT mercygeorge antibodyresponsetosarscov2vaccinationinpatientswithlymphoproliferativedisordersandplasmacelldyscrasiasantilymphomatherapyasapredictivebiomarkerofresponsetovaccination AT abdullateefabdulkareem antibodyresponsetosarscov2vaccinationinpatientswithlymphoproliferativedisordersandplasmacelldyscrasiasantilymphomatherapyasapredictivebiomarkerofresponsetovaccination AT katherineabelden antibodyresponsetosarscov2vaccinationinpatientswithlymphoproliferativedisordersandplasmacelldyscrasiasantilymphomatherapyasapredictivebiomarkerofresponsetovaccination AT pierluigiporcu antibodyresponsetosarscov2vaccinationinpatientswithlymphoproliferativedisordersandplasmacelldyscrasiasantilymphomatherapyasapredictivebiomarkerofresponsetovaccination AT ubaldomartinezoutschoorn antibodyresponsetosarscov2vaccinationinpatientswithlymphoproliferativedisordersandplasmacelldyscrasiasantilymphomatherapyasapredictivebiomarkerofresponsetovaccination AT adamfbinder antibodyresponsetosarscov2vaccinationinpatientswithlymphoproliferativedisordersandplasmacelldyscrasiasantilymphomatherapyasapredictivebiomarkerofresponsetovaccination AT innachervenova antibodyresponsetosarscov2vaccinationinpatientswithlymphoproliferativedisordersandplasmacelldyscrasiasantilymphomatherapyasapredictivebiomarkerofresponsetovaccination AT onderalpdogan antibodyresponsetosarscov2vaccinationinpatientswithlymphoproliferativedisordersandplasmacelldyscrasiasantilymphomatherapyasapredictivebiomarkerofresponsetovaccination |